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204 Learning from clinical scores and registries in STEMI
between qualifying ECG and coronary angiography for PPCI in STEMI patients.
Not following the ESC guidelines was associated with a three-fold increase in
hospital mortality. A similar trend was observed for lytic-treated patients. When
meeting the ESC guidelines for PPCI seems unlikely, timely administration of fib-
rinolysis should be considered.
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Background: France has a highly developed MICU system with emergency
physicians on board the ambulances (SAMU), who have the ability to adminis-
ter recommended medications at a very early stage of AMI.
Aim: To assess in-hospital outcomes in patients transported by the SAMU, in
relation to the pre-hospital administration of antithrombotic medications and time
from symptom onset to first call.
Methods: FAST-MI 2010 is a nationwide French registry that included 4169 pa-
tients with AMI at the end of 2010 in 213 centres. Of those, 2364 had STEMI, of
whom 1868 (79%) were transported by the SAMU and 1836 had the time from
symptom onset to first call recorded (78%).
Results: Time from onset to first call was ≤ 60 minutes in 923 pts (50%), 1172
pts (64%) received an antiplatelet agent, with 1010 receiving dual oral antiplatelet
therapy (DAPT, 55%) in the ambulance. In addition, 27% received enoxaparin and
29% received unfractionated heparin. Patients calling within 60 min of onset had
significantly higher prescription rates of antithrombotic therapy: 71% vs 57%, 62%
vs 48%, 30% vs 24% for any antiplatelet therapy, DAPT, and enoxaparin, respec-
tively. Younger age, male sex, short time from onset to call, absence of diabetes
and lower GRACE score were independent predictors of the use of pre-hospital
antithrombotic medications. Fibrinolytic treatment was administered prehospital in
11% (15% when onset to call ≤ 60 min vs 7% when onset to call > 60 min). When
time from onset to call was ≤60 min, in-hospital mortality was lower with prehos-
pital antithombotic therapy: any antiplatelet 2.3% vs 5.9% (P=0.001), DAPT 1.8%
vs 6.0% (P<0.001), any heparin 1.9 vs 5.7% (P=0.002), prehospital lysis 2.9 vs
3.4% (P=NS). In contrast, prehospital antithrombotic therapy was not associated
with lower in-hospital mortality when time from symptom onset to call was > 60
minutes: 2.7 vs 2.8%, 2.5 vs 3.0%, 2.4 vs 3.0%, 4.8 vs 2.6% respectively (all P =
NS).
Conclusion: The use of prehospital antithrombotic therapy remains suboptimal in
patients managed by physician-staffed ambulances. In patients calling early after
symptom onset, the use of prehospital antithrombotic therapy was associated
with lower in-hospital death; in contrast, in patients calling beyond one hour of
symptom onset, the association with hospital mortality was neutral.
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Background: Hemorrhagic complications are strongly linked with subsequent ad-
verse outcomes in acute coronary syndrome (ACS) patients. Various risk scores
(RS) are available to estimate the bleeding risk in these patients.
Aims: To compare the predictive accuracy of the three contemporary bleeding
RS in ACS.
Methods: We studied 4500 consecutive patients with ACS. For each patient,
the ACTION, CRUSADE, and Mehran et al bleeding RS were calculated. We
assessed their performance either for the prediction of their own major bleed-
ing events or to predict the TIMI serious (major and minor) bleeding episodes
in the overall population, in patients with non-ST elevation ACS (NSTEACS)
and in those with ST-elevation myocardial infarction (STEMI) patients. Calibration
(Hosmer-Lemeshow test) and discrimination (c-statistic) for the three RS were
computed and compared. We used the concept of net reclassification improve-
ment (NRI) to compare the incremental prognostic value of using a particular RS
over the remaining scores in predicting the TIMI serious bleeding.
Results: The best predictive accuracy was obtained by the CRUSADE score ei-
ther for the prediction of its own major bleeding events (c-statistic=0.80, 0.791,
and 0.81 for the entire sample, for STEMI, and for NSTEACS patients, respec-
tively) or to predict the TIMI serious bleed occurrence (c-statistic=0.741, 0.738,
and 0.745 for the whole population, for STEMI and NSTEACS patients, respec-
tively). The lowest bleeding rates observed in patients classified as low risk cor-
responded to the CRUSADE RS. All scores performed modestly in patients who
did not undergo coronariography (all c-statistic <0.70). The CRUSADE score was
significantly superior to the ACTION model in predicting the TIMI serious bleeding
occurrence in terms of NRI overall and by ACS subgroups (p<0.05). Overall, the
CRUSADE RS exhibited better calibration for predicting the TIMI serious bleeding
compared to the ACTION and Mehran et al scores (Hosmer-Lemeshow p-values
of 0.26, 0.13, and 0.07, respectively).
Conclusion: The CRUSADE score represents, among the more contemporary
bleeding RS, the most accurate and reliable quantitative clinical tool in STEACS
and STEMI patients. We encourage the utilization of the CRUSADE index for
bleeding risk stratification purposes in daily clinical practice and in ACS outcome
studies. The performance of the three more contemporary bleeding RS is modest
in those patients who received conservative management.
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Background: In patients with AMI, the choice between clopidogrel and prasugrel
requires information that is not always available at the early phase, such as indi-
cation for PCI or assessment of bleeding and thrombosis risk. When initial clopi-
dogrel treatment seems sub-optimal, switching to prasugrel seems attractive, but
is not yet recommended. We assessed baseline characteristics and in-hospital
outcomes in prasugrel-treated patients, according to the initial use of clopidogrel
before prasugrel initiation.
Methods: FAST-MI 2010 is a nationwide French registry that included 4169 pa-
tients with AMI in 213 centres. In total, 4115 received thienopyridines, of whom
1259 received prasugrel (31%). Among these, 391 received “de novo” prasugrel
(G1), 807 (64%) were treated with clopidogrel first and then switched to prasug-
rel (G2), of whom 11% had a 60mg loading dose of prasugrel. We excluded 61
pts who received prasugrel initially and subsequently switched to clopidogrel. We
compared baseline characteristics, bleeding and ischemic complications between
G1 and G2, and then used propensity-score matching (propensity to be treated
with prasugrel) to compare outcomes in 2 cohorts with similar baseline charac-
teristics.
Results: Age and sex were similar in G1 and G2; more G2 pts had a history of
AMI (13% vs 8%, P=0.01), PCI (14% vs 9.5%, P=0.02), underwent PCI during the
hospital stay (96% vs 93%, P=0.047) or received lytic treatment for STEMI (21%
vs 5%, P<0.001). With the exception of major bleeding, which was less frequent
in G2 (0 vs 1.0%, P=0.004), none of the other complications differed significantly
(Table). The 2 propensity-score matched cohorts (316 patients each) had com-
pletely similar baseline characteristics and 96% (switch clopidogrel to prasugrel)
vs 94% (prasugrel only) followed the recommended indication for prasugrel use;
none of the complications differed significantly (switch vs no switch): any bleeding
(4.1 vs 6.6%), major bleeding (0 vs 0.3%), stent thrombosis (1.3 vs 0.9%), stroke
(0.3 vs 0%), reinfarction (1.3 vs 0.6%), in-hospital death (0.3 vs 0.3%).
Conclusion: In this real-world registry, a high proportion of patients treated with
prasugrel were switched from clopidogrel therapy (64%). There was no evidence
of excess risk of bleeding or in-hospital complications in the patients who were
switched, compared with those who received prasugrel treatment only. Further
randomized studies are mandatory to determine the safety and efficacy of this
strategy.
1390 Major improvement in early mortality of AMI over the
past 15 years in relation to management changes: data
from 4 nationwide French surveys
E. Puymirat1, G. Steg2, D. Blanchard3, P. Goldstein4, M. Hanssen5,
E. Durand1, P. Gueret6, J.P. Cambou7, T. Simon8, N. Danchin1 on
behalf of the FAST-MI 2010 investigators. 1AP-HP - European Hospital Georges
Pompidou, Paris, France; 2AP-HP - Hospital Bichat-Claude Bernard, Department
of Cardiology, Paris, France; 3Clinic Saint Gatien, Tours, France; 4Hospital
Regional University of Lille, Department of Emergency, Lille, France; 5General
Hospital of Haguenau, Department of Cardiology, Haguenau, France; 6AP-HP
- University Hospital Henri Mondor, Department of Cardiology, Creteil, France;
7University Hospital of Toulouse, Department of Epidemiology, Inserm U558,
Toulouse, France; 8AP-HP - Hospital Saint-Antoine, Faculty of Medicine Pierre &
Marie Curie Paris 6, Paris, France
Background and aim: The management of AMI has undergone profound






/eurheartj/article/33/suppl_1/19/430790 by na user on 01 February 2021
